Pfizer's Weak Q2 Sales Highlight Dependence On The Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales in almost all of Pfizer's key pharmaceutical businesses fell in the second quarter, sending the company's stock price down 4.5%.